These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 18384577

  • 1. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P.
    J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
    [Abstract] [Full Text] [Related]

  • 2. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM].
    Maron BJ, Spirito P.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):297-302. PubMed ID: 19791462
    [Abstract] [Full Text] [Related]

  • 3. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [Abstract] [Full Text] [Related]

  • 4. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.
    JAMA; 2007 Jul 25; 298(4):405-12. PubMed ID: 17652294
    [Abstract] [Full Text] [Related]

  • 5. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS.
    J Am Coll Cardiol; 2013 Apr 09; 61(14):1527-35. PubMed ID: 23500286
    [Abstract] [Full Text] [Related]

  • 6. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA, Spirito P.
    N Engl J Med; 2000 Feb 10; 342(6):365-73. PubMed ID: 10666426
    [Abstract] [Full Text] [Related]

  • 8. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA, Spencer WH, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton JM, Gold MR.
    J Am Coll Cardiol; 2008 Nov 18; 52(21):1718-23. PubMed ID: 19007692
    [Abstract] [Full Text] [Related]

  • 9. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H.
    Kardiol Pol; 2005 Oct 18; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [Abstract] [Full Text] [Related]

  • 10. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
    McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ.
    Eur Heart J; 2007 Nov 18; 28(21):2583-8. PubMed ID: 17483110
    [Abstract] [Full Text] [Related]

  • 11. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA.
    Heart; 2009 May 18; 95(9):709-14. PubMed ID: 19282314
    [Abstract] [Full Text] [Related]

  • 12. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy.
    Cha YM, Gersh BJ, Maron BJ, Boriani G, Spirito P, Hodge DO, Weivoda PL, Trusty JM, Friedman PA, Hammill SC, Rea RF, Shen WK.
    J Cardiovasc Electrophysiol; 2007 May 18; 18(5):483-7. PubMed ID: 17343723
    [Abstract] [Full Text] [Related]

  • 13. [Interventional treatment in hypertrophic cardiomyopathy].
    Gietzen FH, Schümmelfeder J, Neuser H, Brunn J, Schumacher B, Kerber S.
    Herz; 2005 Mar 18; 30(2):102-10. PubMed ID: 15875098
    [Abstract] [Full Text] [Related]

  • 14. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Neves JP, Bonhosrst D, Gomes JL, Gomes RS.
    Rev Port Cardiol; 2005 Mar 18; 24(3):407-15. PubMed ID: 15929624
    [Abstract] [Full Text] [Related]

  • 15. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S.
    Circulation; 2008 Apr 15; 117(15):1918-26. PubMed ID: 18391108
    [Abstract] [Full Text] [Related]

  • 16. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M, Krebs A, Nitardy A, Habedank D, Celebi O, Knaus T, Dietz R.
    Pacing Clin Electrophysiol; 2009 Mar 15; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [Abstract] [Full Text] [Related]

  • 17. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu Vilsendorf D, Beer G, Kuhn H.
    Pacing Clin Electrophysiol; 2005 Apr 15; 28(4):295-300. PubMed ID: 15826262
    [Abstract] [Full Text] [Related]

  • 18. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, Sanborn DM, Picard MH, Vlahakes GJ, Mela T, Das S.
    Am J Cardiol; 2009 Jul 01; 104(1):128-32. PubMed ID: 19576333
    [Abstract] [Full Text] [Related]

  • 19. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
    Healey JS, Hallstrom AP, Kuck KH, Nair G, Schron EP, Roberts RS, Morillo CA, Connolly SJ.
    Eur Heart J; 2007 Jul 01; 28(14):1746-9. PubMed ID: 17283003
    [Abstract] [Full Text] [Related]

  • 20. ST-segment depression as a risk factor in hypertrophic cardiomyopathy.
    Haghjoo M, Mohammadzadeh S, Taherpour M, Faghfurian B, Fazelifar AF, Alizadeh A, Rad MA, Sadr-Ameli MA.
    Europace; 2009 May 01; 11(5):643-9. PubMed ID: 19164362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.